Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing
  The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a
million deaths, high morbidities, and economic distress worldwide. There is an
urgent need to identify medications that would treat and prevent novel diseases
like the 2019 coronavirus disease (COVID-19). Drug repurposing is a promising
strategy to discover new medical indications of the existing approved drugs due
to several advantages in terms of the costs, safety factors, and quick results
compared to new drug design and discovery. In this work, we explore
computational data-driven methods for drug repurposing and propose a dedicated
graph neural network (GNN) based drug repurposing model, called Dr-COVID.
Although we analyze the predicted drugs in detail for COVID-19, the model is
generic and can be used for any novel diseases. We construct a four-layered
heterogeneous graph to model the complex interactions between drugs, diseases,
genes, and anatomies. We pose drug repurposing as a link prediction problem.
Specifically, we design an encoder based on the scalable inceptive graph neural
network (SIGN) to generate embeddings for all the nodes in the four-layered
graph and propose a quadratic norm scorer as a decoder to predict treatment for
a disease. We provide a detailed analysis of the 150 potential drugs (such as
Dexamethasone, Ivermectin) predicted by Dr-COVID for COVID-19 from different
pharmacological classes (e.g., corticosteroids, antivirals, antiparasitic). Out
of these 150 drugs, 46 drugs are currently in clinical trials. Dr-COVID is
evaluated in terms of its prediction performance and its ability to rank the
known treatment drugs for diseases as high as possible. For a majority of the
diseases, Dr-COVID ranks the actual treatment drug in the top 15.
